This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hajjar, R. J. Articles by Rosenzweig, A. Search for Related Content PubMed PubMed Citation Articles by Hajjar, R. J. Articles by Rosenzweig, A. Related Collections Calcium cycling/excitation-contraction coupling Heart failure - basic studies Gene therapy

(Circulation Research. 2000;86:616.)
© 2000 American Heart Association, Inc.

MiniReview

Prospects for Gene Therapy for Heart Failure

Roger J. Hajjar, Federica del Monte, Takashi Matsui, Anthony Rosenzweig

From the Program in Cardiovascular Gene Therapy, Cardiovascular Research Center, and Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Anthony Rosenzweig, Cardiovascular Research Center, Massachusetts General Hospital—East, 149 13th St, 4th Floor, Room 4214, Charlestown, MA 02129. E-mail rosenzweig{at}helix.mgh.harvard.edu

	Abstract

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
Abstract—Heart failure represents an enormous clinical challenge in need of effective therapeutic approaches. The possibility of gene therapy for heart failure merits consideration at this time because of improvements in vector technology; cardiac gene delivery; and, most importantly, our understanding of the molecular pathogenesis of heart failure. We will first review recent advances in cardiac gene delivery in animal models and then examine several targets being considered for therapeutic intervention. In this context, gene transfer provides not only a potential therapeutic modality but also an important tool to help validate specific targets. Several interventions, particularly those enhancing sarcoplasmic calcium transport, show promise in animal models of heart failure and in myopathic cardiomyocytes derived from patients. However, bridging the gap between these basic investigative studies and clinical gene therapy remains a formidable task. Early experiments in rodents will need to be extended to large-animal models with clinical-grade vectors and delivery systems to assess both efficacy and safety. On the basis of a foundation of rigorous science and a growing understanding of heart failure pathogenesis, there is reason for cautious optimism for the future.

Key Words: gene therapy • heart failure • Ca²⁺ cycling • excitation-contraction coupling

	Introduction

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
Many considerations make heart failure an appealing clinical candidate for gene therapy. Heart failure is an increasingly common clinical problem that is only partly mitigated by our current pharmacological therapy. In contrast to the decreasing mortality from coronary disease, heart failure deaths more than doubled from 1979 to 1995.¹ In part, this may reflect the aging demographics of the US population, because the rates of new and recurrent heart failure events increase substantially with age.¹ As with cancer, the poor prognosis of specific subsets of heart failure patients heightens interest in novel therapeutic approaches. This interest is further intensified, because the elderly population in which heart failure is most common has generally been excluded from consideration for cardiac transplantation. Moreover, in contrast to younger patients with more favorable prognoses, waiting years for vector improvements may not be a realistic option for the heart failure patient, and the fact that treatment with current vectors may preclude future administration because of overlapping immune responses may have little practical consequence. Although vector delivery is not a trivial problem, the well-circumscribed geography of the heart makes it an attractive target that benefits from a wealth of clinical interventional experience. A variety of catheter or surgical approaches to in vivo cardiac gene transfer show promise in animal and clinical studies. Although achieving "lifelong" transgene expression may be more feasible in this population than in infants with inborn errors of metabolism, there may also be clinical settings in which transgene expression would be required only during a period of defined risk, such as remodeling after myocardial infarction. Importantly, a variety of animal models of heart failure exist that reasonably reflect the human condition and have previously paved the way for clinical therapies.^{2 3} Moreover, a sophisticated array of clinical tools are currently available to evaluate objectively the functional consequences of any intervention. Thus, potential gene-based therapies for heart failure could be validated in realistic animal models and, when appropriate, rigorously analyzed in clinical trials for effects on both physiological and clinical endpoints.

Clinical success in any application of gene therapy will require 3 essential elements appropriate to the specific setting. First, a vector or packaging system is necessary for the genetic material that will be delivered. To a large extent, features of the vector determine the range of host cells that can be transduced, as well as the efficiency, level, and duration of transgene expression. Of note, only a few of the currently available vectors achieve efficient, high-level transgene expression in postmitotic cells, such as cardiomyocytes. These include recombinant adenoviruses (see below), adeno-associated viruses,⁴ and possibly lentivirus.⁵ The interested reader is referred to a more detailed discussion of available vector systems.⁶ Secondly, the vector must be delivered to the affected tissues. This poses a particularly formidable barrier in conditions with an extensively distributed phenotype and may be more achievable in conditions localized to one organ, such as the heart. Finally, an appropriate gene to be expressed in a particular clinical setting must be identified. Over the past decade, there have been substantial advances in all 3 of these areas that provide the basis for a renewed but cautious optimism that gene therapy may prove clinically useful in specific settings. However, it is important to acknowledge that the field of gene therapy has not yet proven its clinical value in any context. Moreover, this laudable long-term goal is likely to be achieved only through a logical progression of rigorous basic and clinical investigation. In this review, we will first highlight recent progress toward achieving effective, global cardiac gene transfer in vivo and then outline some of the molecular pathways being considered for gene therapy in heart failure.

	Cardiac Gene Delivery

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
The feasibility of in vivo cardiac gene transfer by viral vectors has been consistently demonstrated over the last few years.^{7 8 9} Recombinant adenoviruses have been the most common vectors used in these initial studies largely because of their flexible packaging constraints and their ability to transduce nonreplicating cells. However, the robust immune response these vectors evoke suggests that clinical applications will likely require other vectors or further refined adenoviral systems. A number of mechanical approaches have been used to achieve cardiac gene transfer, as shown in Figure 1. Intracoronary catheter delivery of an adenovirus encoding ß-galactosidase achieved transduction of 30% of the myocytes in the distribution of the coronary artery.¹⁰ Direct injection of adenovirus into the ventricular wall using an epicardial approach has also been shown to induce significant expression of reporter constructs; however, the expression was focal, and the injections within the myocardium caused needle damage.^{9 10 11} Intramyocardial delivery of adenovirus using an intraventricular approach with retroinfusion of coronary veins has also been used in larger animals yielding regional areas of transduction.¹² In rodents, injection of an adenovirus carrying ß-galactosidase into the pericardial sac transduced only the pericardial cell layers.¹³ The addition of collagenase and hyaluronidase together with the adenovirus led to a larger diffusion of the transgene activity within the ventricle.¹³ Effective therapy in heart failure will likely require a gene delivery method capable of globally transducing the myocardium. Using intracoronary perfusion in explanted hearts, Donahue et al¹⁴ reported highly effective gene transfer to the heart and identified critical parameters influencing the efficiency of adenoviral gene transfer.¹⁴ These included (1) the use of crystalloid solution as opposed to whole blood, (2) high coronary flow rate, (3) exposure time, (4) virus concentration, and (5) temperature. More recently, Donahue et al¹⁴ found that decreasing perfusate Ca²⁺ concentration, or pretreating with serotonin or bradykinin, significantly decreased the exposure time necessary to achieve widespread infection.¹⁵ To achieve diffuse cardiac gene transfer in vivo, we recently developed a catheter-based technique in rodents.¹⁶ In this approach, a catheter is inserted in the left ventricular apex and advanced beyond the aortic valve. A high-concentration adenoviral preparation is then injected through the catheter (Figure 1E) while the aorta and pulmonary artery are cross-clamped distal to the catheter tip for a period of 10 to 40 seconds. This method achieves grossly homogeneous transduction of cardiac myocytes throughout the left and right ventricles of the heart.¹⁶ More importantly, this technique can produce dramatic, transgene-specific physiological effects on ventricular function in vivo.¹⁶ The success of this approach likely reflects in vivo optimization of the parameters previously shown to be important for ex vivo gene transfer,¹⁴ as well as high-perfusion pressure that presumably allows the opening of capillaries and optimizes the myocardial area of virus exposure. Other investigators have confirmed the effectiveness of similar approaches in other animal models. Recently, Maurice et al¹⁷ used this technique to express ß₂ receptors in rabbit hearts; however, they only clamped the aorta (Figure 1D) and achieved predominantly epicardial transgene expression. By cross-clamping both the pulmonary artery and the aorta, the left ventricular end-diastolic pressure does not increase, because blood return to the left ventricle is minimal.¹⁶ This allows perfusion of the virus at relatively low downstream pressure, and the endocardium can be efficiently infected. Correlates of this method in humans have not yet been established. However, it is noteworthy that aortic occlusion during aortic valvuloplasty is well tolerated in generally ill patients for periods of time comparable with those required for gene transfer in animal models.^{18 19} Optimizing conditions for gene transfer in large animals and eventually humans will require substantial further investigation.

View larger version (43K): [in this window] [in a new window]   Figure 1. Different techniques used to date for in vivo cardiac gene transfer. A, Coronary perfusion. B, Intramyocardial injection. C, Pericardial injection. D, Aortic clamping. E, Cross-clamping of the aorta and pulmonary artery. SVC indicates superior vena cava; IVC, inferior vena cava.

	Gene Targets

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
Cardiac myocytes isolated from failing hearts are characterized by a number of abnormalities that affect excitation-contraction coupling. These include changes at the level of the sarcolemma, sarcoplasmic reticulum (SR), myofilaments, and mitochondria, all of which contribute to depressed contractile function and reserve. Identifying the mechanisms by which these changes contribute to the observed pathology is frequently confounded by simultaneous alterations in multiple signaling pathways in the complex milieu of the failing heart. Targeting genes to the heart through somatic gene transfer allows us to assess the efficacy of highly specific interventions in models of heart failure. Recent work using gene transfer in animal models has helped identify potential molecular targets for therapy in heart failure.

Calcium Handling
In the heart, [Ca²⁺]_i is tightly regulated at several levels. The SR plays an important role in orchestrating the movement of calcium during each contraction and relaxation. As shown in Figure 2, excitation leads to the opening of voltage-gated L-type Ca²⁺ channels, allowing the entry of a small amount of Ca²⁺ into the cell. Through coupling of the L-type Ca²⁺ channel and the SR release channels (ryanodine receptors), a larger amount of Ca²⁺ is released, activating the myofilaments and leading to contraction. During relaxation, Ca²⁺ is reaccumulated in the SR by the SR Ca²⁺ ATPase pump (SERCA2a) and extruded extracellularly by the sarcolemmal Na/Ca exchanger. The contribution of each of these mechanisms toward lowering cytosolic Ca²⁺ varies with species. In humans, 75% of the Ca²⁺ is removed by SERCA2a and 25% by the Na/Ca exchanger.²⁰ The Ca²⁺ pumping activity of SERCA2a is influenced by phospholamban.²¹ In the unphosphorylated state, phospholamban inhibits the Ca²⁺-ATPase, whereas phosphorylation of phospholamban by cAMP-dependent protein kinase and by Ca²⁺-calmodulin–dependent protein kinase reverses this inhibition.²¹ Studies in cardiac muscle strips, trabeculae, or single cardiomyocytes from failing hearts show reduced systolic force, elevated diastolic force, and slowed relaxation, as well as prolonged Ca²⁺ transient with an elevated end-diastolic [Ca²⁺]_i.^{22 23 24 25 26 27} A decrease in SR Ca²⁺ ATPase activity and Ca²⁺ uptake appears responsible for abnormal Ca²⁺ homeostasis not only in animal models but also in human heart failure.²⁸ Associated with a defective Ca²⁺ uptake, there is a decrease in the relative ratio of SERCA2a/phospholamban in these failing hearts.^{29 30 31} Using transgenic and gene transfer approaches, increasing levels of phospholamban relative to SERCA2a in isolated cardiac myocytes significantly altered intracellular Ca²⁺ handling by prolonging the relaxation phase of the Ca²⁺ transient, decreasing Ca²⁺ release, and increasing resting Ca²⁺.^{29 30 32 33}

View larger version (49K): [in this window] [in a new window]   Figure 2. Ca2+ handling proteins involved in Ca2+ movement.

These results support the hypothesis that an abnormal ratio of phospholamban to SERCA2a contributes significantly to abnormalities in Ca²⁺ handling and contraction observed in failing ventricular myocardium, but leave answered the questions about the benefit that would be derived from restoring this ratio through gene transfer. In neonatal rat myocytes in vitro, overexpression of SERCA2a largely "rescued" the phenotype created by increasing the phospholamban-to-SERCA2a ratio.²⁹ More importantly, in human cardiomyocytes isolated from the left ventricles of patients with end-stage heart failure, gene transfer of SERCA2a resulted in an increase in both protein expression and pump activity and induced a faster contraction velocity and enhanced relaxation velocity, restoring these parameters to levels observed in nonfailing hearts.³⁴ Furthermore, diastolic Ca²⁺ was decreased in failing human cardiomyocytes overexpressing SERCA2a, whereas systolic Ca²⁺ was increased and the frequency response was normalized.³⁴ These in vitro models may not reflect the behavior of intact hearts. However, in an animal model of pressure-overload hypertrophy in transition to failure, in which SERCA2a protein levels and activity are decreased and severe contractile dysfunction is present, overexpression of SERCA2a by gene transfer in vivo (using the technique described above) restored both systolic and diastolic function to normal levels.³⁵ Overexpression of SERCA2a decreased left ventricular size and restored the slope of the end-systolic pressure–dimension relationship, a load-independent parameter of contractility, to control levels.³⁵ These recent studies provide strong evidence that overexpression of SERCA2a to rescue disturbed Ca²⁺ cycling and myocardial function of the failing heart is indeed possible and suggest the feasibility of cardiac gene transfer in failing hearts as a therapeutic modality. The effective SERCA2a/phospholamban ratio can also be normalized by decreasing or inhibiting phospholamban. Overexpression of an antisense phospholamban construct or a dominant-negative mutant of phospholamban has recently been shown to enhance SERCA2 activity.³⁶ This is consistent with the observation that genetic ablation of phospholamban prevents the functional abnormalities otherwise seen in a mouse model of dilated cardiomyopathy.³⁷ Of note, increased SR Ca²⁺ ATPase activity, however, achieved decreases in intracellular diastolic Ca²⁺ by increasing uptake into the SR and enhancing Ca²⁺ release. Thus, in addition to the contractile benefits of SERCA2a expression, diastolic Ca²⁺ is decreased, which may help prevent activation of signaling molecules, including calcineurin and stress-activated protein kinases (SAPKs) capable of inducing myocyte hypertrophy and cell death.^{38 39 40 41}

ß-Adrenergic Signaling
Other pathways in excitation-contraction coupling also provide targets for intervention in heart failure. ß-Adrenergic signaling defects, including downregulation of myocardial ß-adrenergic receptors (ß-AR), ß-AR uncoupling, and upregulation of the ß-AR kinase (ß ARK1), are central features of human and animal heart failure.^{42 43} In isolated ventricular myocytes from a model of heart failure in the rabbit, adenoviral gene transfer of the human ß2-AR or an inhibitor of ß ARK1 led to the restoration of ß-AR signaling and an increase in cytosolic cAMP levels.⁴⁴ This study, along with the finding that overexpression of an inhibitor of ß ARK1 prevents the development of cardiomyopathy in a murine model of heart failure,⁴⁵ emphasizes the importance of ß-adrenergic signaling defects in the pathogenesis of heart failure and raises the possibility that targeting this system may restore function in failing cardiomyocytes. However, stimulation of the ß-adrenergic system induces an increase in intracellular cAMP that, when sustained, can be cardiotoxic and arrhythmogenic.⁴⁶ It is possible that this mechanism may underlie the clinical observation that inotropic interventions that increase cellular cAMP increase mortality in chronic heart failure.⁴⁷ In fact, a recent study found that in mice overexpressing ß₂-adrenergic receptors, development of heart failure was exacerbated when these mice were subjected to aortic stenosis.⁴⁸ Moreover, the transgenic mice had more severe left ventricular dysfunction and higher incidence of premature deaths.⁴⁸ Nevertheless, the critical role of the ß-adrenergic pathway suggests further investigation of this pathway as a target for intervention despite the cautionary clinical and experimental experience of direct ß-agonism.

Apoptosis
In response to specific stimuli, cells can activate intrinsic suicide pathways and undergo programmed cell death or apoptosis. Morphological and biochemical markers of apoptosis have been identified in a wide variety of cardiac conditions, including experimental^{49 50 51} and human heart failure,^{52 53 54} suggesting that these pathways may contribute to cardiomyocyte loss and cardiac dysfunction in heart failure. Cardiac-specific deletion of the signaling receptor subunit, gp130, leads to massive cardiac apoptosis and accelerated dilated cardiomyopathy after aortic banding,⁵⁵ suggesting a functional role of apoptosis in heart failure that may represent an additional target for therapeutic intervention.⁵⁶ In cardiomyocytes, manipulating a number of conserved pathways through somatic gene transfer can block apoptosis in response to a variety of stimuli. Overexpression of Bcl-2 through adenoviral gene transfer blocks p53-induced apoptosis in ventricular cardiomyocytes.⁵⁷ This observation is consistent with the powerful protective effect of antiapoptotic Bcl family members in a variety of cell systems. In addition, a number of "viability factors" have been identified that can play an important role in modulating apoptosis. These include growth factors, such as insulin-like growth factor-I (IGF-I), which blocks apoptosis in many settings, including models of cardiac ischemia-reperfusion injury.⁵⁸ The ability of IGF-I to block apoptosis is often dependent on activation of phosphatidylinositol (PI) 3–kinase⁵⁹ and, in some systems, its downstream target, Akt.⁶⁰ Adenoviral gene transfer of activated forms of PI 3-kinase and Akt can block hypoxia-induced cardiomyocyte apoptosis in vitro.⁶¹ There is also some evidence that the SAPKs (especially p38) may be involved in cardiac apoptosis. Stimulation of p38 in cardiac myocytes induced apoptosis, which was abrogated by gene transfer of a dominant-negative p38 mutant.⁶² The ability to block cardiomyocyte apoptosis through somatic gene transfer with such vectors should allow us to examine the functional significance of specific pathways and apoptosis in general in animal models of heart failure to determine whether these pathways hold promise as targets for clinical intervention.⁶³

	Future Directions

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
Heart failure represents a growing clinical challenge in need of novel therapeutic approaches. Improvements in vector technology; cardiac gene delivery; and, most importantly, our understanding of the molecular pathogenesis of heart failure, prompt careful consideration of gene therapy for heart failure at this time. Several interventions, particularly those enhancing sarcoplasmic calcium transport, show therapeutic promise in animal models of heart failure and in myopathic cardiomyocytes derived from patients. In this effort, somatic gene transfer provides an important tool to help understand the relative contribution of specific pathways and validate molecular targets for therapeutic intervention, whether pharmacological or genetic. Nevertheless, bridging the gap between these basic investigative studies and clinical gene therapy remains a formidable but not insurmountable task. Early proof of concept experiments in rodents will need to be extended to large-animal models with clinical-grade vectors and delivery systems to assess both efficacy and safety. On the basis of a foundation of rigorous science and a growing understanding of heart failure pathogenesis, there is reason for cautious optimism for the future.

	This MiniReview is part of a thematic series on Cardiovascular Gene Therapy, which includes the following articles:

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 
Prospects for Gene Therapy for Heart Failure

Gene Therapy for Disorders of the Vascular Wall Vectors for Gene Therapy Gene Therapy for Coagulation Disorders Ongoing Gene Therapy Clinical Trials Gene Therapy for Hypertension

Charles Lowenstein, Toren Finkel, Eduardo Marbán, Editors

	Acknowledgments

 
This work was supported in part by NIH Grants HL50361 and HL57623 (to R.J.H.) and HL59521 and HL61557 (to A.R.). R.J.H. is a recipient of the Doris Duke Clinical Scientist Award. A.R. is an Established Investigator of the American Heart Association. We thank Dr Thomas Force for his insightful suggestions. The assistance of Paula Kaltofen with manuscript preparation is greatly appreciated.

Received December 29, 1999; accepted January 27, 2000.

	References

Top Abstract Introduction Cardiac Gene Delivery Gene Targets Future Directions This MiniReview is part... References

 

1. American Heart Association web site. Available at www.americanheart.org/statistics.
2. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 1991;260:H1406–H1414.[Abstract/Free Full Text]
3. Mitchell GF, Pfeffer JM, Pfeffer MA. The transition to failure in the spontaneously hypertensive rat. Am J Hypertens. 1997;10:120S–126S.[Medline] [Order article via Infotrieve]
4. Svensson EC, Marshall DJ, Woodard K, Lin H, Jiang F, Chu L, Leiden JM. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation. 1999;99:201–205.[Abstract/Free Full Text]
5. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol. 1999;31:2037–2047.[Medline] [Order article via Infotrieve]
6. Rosenzweig A. Vectors for gene therapy. In: Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC, Seidman CE, Seidman JG, Smith DR, eds. Current Protocols in Human Genetics. New York, NY: John Wiley & Sons, Inc; 1999:12.10.11–12.18.19.
7. Kirshenbaum LA, MacLennan WR, Mazur W, French BA, Schneider MD. Highly efficient gene transfer into adult ventricular myocytes by recombinant adenovirus. J Clin Invest. 1993;92:381–387.
8. Kass-Eisler A, Falck-Pedersen E, Alvira M, Rivera J, Buttrick PM, Wittenberg BA, Cipriani L, Leinwand LA. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and vivo. Proc Natl Acad Sci U S A. 1993;90:11498–11502.[Abstract/Free Full Text]
9. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res. 1993;73:1202–1207.[Abstract/Free Full Text]
10. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, Leiden JM. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1994;1:51–58.[Medline] [Order article via Infotrieve]
11. French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 1994;90:2414–2424.[Abstract/Free Full Text]
12. Boeckstegers P, von Degenfeld G, Heinrich D, Hullin R, Kupatt C, Giehrl WF, Franz WM. Regional myocardial gene transfer using high efficiency with selective pressure-regulated retroinfusion of coronary veins. Circulation. 1999;100(suppl I):I-815.
13. Fromes Y, Salmon A, Wang X, Collin H, Rouche A, Hagege A, Schwartz K, Fiszman MY. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 1999;6:683–688.[Medline] [Order article via Infotrieve]
14. Donahue JK, Kikkawa K, Johns DC, Marbán E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A. 1997;94:4664–4668.[Abstract/Free Full Text]
15. Donahue JK, Kikkawa K, Thomas AD, Marbán E, Lawrence JH. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther. 1998;5:630–634.[Medline] [Order article via Infotrieve]
16. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ, Rosenzweig A. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A. 1998;95:5251–5256.[Abstract/Free Full Text]
17. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC, Wilson KH, Lefkowitz RJ, Glower DD, Koch WJ. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest. 1999;104:21–29.[Medline] [Order article via Infotrieve]
18. Block PC, Palacios IF. Clinical and hemodynamic follow-up after percutaneous aortic valvuloplasty in the elderly. Am J Cardiol. 1988;62:760–763.[Medline] [Order article via Infotrieve]
19. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol. 1994;23:1071–1075.[Abstract]
20. Hasenfuss G. Calcium pump overexpression and myocardial function: implications for gene therapy of myocardial failure. Circ Res. 1998;83:966–968.[Free Full Text]
21. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996;79:1059–1063.[Free Full Text]
22. Gwathmey JK, Morgan JP. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res. 1985;57:836–843.[Abstract/Free Full Text]
23. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61:70–76.[Abstract/Free Full Text]
24. Gwathmey JK, Hajjar RJ. Relation between steady-state force and intracellular [Ca²⁺] in intact human myocardium: index of myofibrillar responsiveness to Ca²⁺. Circulation. 1990;82:1266–1278.[Abstract/Free Full Text]
25. Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest. 1990;85:1599–1613.
26. Gwathmey JK, Bentivegna LA, Ransil BJ, Grossman W, Morgan JP. Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardium. Cardiovasc Res. 1993;27:199–203.[Abstract/Free Full Text]
27. Gwathmey JK, Morgan JP. Sarcoplasmic reticulum calcium mobilization in right ventricular pressure-overload hypertrophy in the ferret: relationships to diastolic dysfunction and a negative treppe. Pflugers Arch. 1993;422:599–608.[Medline] [Order article via Infotrieve]
28. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, Gwathmey JK. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 1998;30:1929–1937.[Medline] [Order article via Infotrieve]
29. Hajjar RJ, Schmidt U, Kang JX, Matsui T, Rosenzweig A. Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes: rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca²⁺ ATPase. Circ Res. 1997;81:145–153.[Abstract/Free Full Text]
30. Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation. 1997;95:423–429.[Abstract/Free Full Text]
31. Meyer M, Bluhm WF, He H, Post SR, Giordano FJ, Lew WY, Dillmann WH. Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am J Physiol. 1999;276:H779–H785.[Abstract/Free Full Text]
32. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW 2nd, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533–539.[Medline] [Order article via Infotrieve]
33. Davia K, Hajjar RJ, Terracciano CMN, Kent NS, Ranu HK, O’Gara P, Rosenzweig A, Harding SE. Functional alterations in adult rat myocytes following overexpression of phospholamban using adenovirus. Physiol Genomics. 1999;1:41–50.[Abstract/Free Full Text]
34. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308–2311.[Abstract/Free Full Text]
35. Miyamoto MI, del Monte F, Schmidt U, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97:793–798.[Abstract/Free Full Text]
36. He H, Meyer M, Martin JL, McDonough PM, Ho P, Lou X, Lew WY, Hilal-Dandan R, Dillmann WH. Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation. 1999;100:974–980.[Abstract/Free Full Text]
37. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J, Kranias E, Giles WR, Chien KR. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical cycling defect in dilated cardiomyopathy. Cell. 1999;99:313–322.[Medline] [Order article via Infotrieve]
38. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest. 1998;102:1311–1320.[Medline] [Order article via Infotrieve]
39. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero J, Picard M, Rosenzweig A, Force T. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest. 1999;104:391–398.[Medline] [Order article via Infotrieve]
40. Force T, Rosenzweig A, Choukroun G, Hajjar R. Calcineurin inhibitors and cardiac hypertrophy. Lancet. 1999;353:1290–1292.[Medline] [Order article via Infotrieve]
41. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999;5:246–247.[Medline] [Order article via Infotrieve]
42. Bohm M, Flesch M, Schnabel P. Beta-adrenergic signal transduction in the failing and hypertrophied myocardium. J Mol Med. 1997;75:842–848.[Medline] [Order article via Infotrieve]
43. Hajjar RJ, Muller FU, Schmitz W, Schnabel P, Bohm M. Molecular aspects of adrenergic signal transduction in cardiac failure. J Mol Med. 1998;76:747–755.[Medline] [Order article via Infotrieve]
44. Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC, Glower DD, Lefkowitz RJ, Koch WJ. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1997;94:12100–12105.[Abstract/Free Full Text]
45. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000–7005.[Abstract/Free Full Text]
46. Mann DL, Kent RL, Parsons B, Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804.[Abstract/Free Full Text]
47. Stevenson LW. Inotropic therapy for heart failure. N Engl J Med. 1998;339:1848–1850.[Free Full Text]
48. Du X-J, Autelitano DJ, Dilley RJ, Wang B, Dart AM, Woodcock EA. ß2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation. 2000;101:71–77.[Abstract/Free Full Text]
49. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 1996;148:141–149.[Abstract]
50. Sharov VG, Sabbah HN, Ali AS, Shimoyama H, Lesch M, Goldstein S. Abnormalities of cardiocytes in regions bordering fibrous scars of dogs with heart failure. Int J Cardiol. 1997;60:273–279.[Medline] [Order article via Infotrieve]
51. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol. 1997;272:H2313–H2319.[Abstract/Free Full Text]
52. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie DF, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw B-A. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–1189.[Abstract/Free Full Text]
53. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di LC, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–1141.[Abstract/Free Full Text]
54. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, Dal Bello B, Semigran MJ, Bielsa-Masdeu A, Dec GW, Israels S, Ballester M, Virmani R, Saxena S, Kharbanda S. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 1999;96:8144–8149.[Abstract/Free Full Text]
55. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W, Chien KR. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189–198.[Medline] [Order article via Infotrieve]
56. Williams RS. Apoptosis and heart failure. N Engl J Med. 1999;341:759–760.[Free Full Text]
57. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation. 1997;96:1580–1585.[Abstract/Free Full Text]
58. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A. 1995;92:8031–8035.[Abstract/Free Full Text]
59. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995;267:2003–2006.[Abstract/Free Full Text]
60. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275:661–665.[Abstract/Free Full Text]
61. Matsui T, Li L, del Monte F, Fukui Y, Franke T, Hajjar R, Rosenzweig A. Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999;100:2373–2379.[Abstract/Free Full Text]
62. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161–2168.[Abstract/Free Full Text]
63. Haunstetter A, Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res. 2000;86:371–376.[Free Full Text]

This article has been cited by other articles:

				B. Heidecker, E. K. Kasper, I. S. Wittstein, H. C. Champion, E. Breton, S. D. Russell, M. M. Kittleson, K. L. Baughman, and J. M. Hare Transcriptomic Biomarkers for Individual Risk Assessment in New-Onset Heart Failure Circulation, July 15, 2008; 118(3): 238 - 246. [Abstract] [Full Text] [PDF]

				E. Braunwald The Management of Heart Failure: The Past, the Present, and the Future Circ Heart Fail, May 1, 2008; 1(1): 58 - 62. [Full Text] [PDF]

				M. Periasamy, P. Bhupathy, and G. J. Babu Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology Cardiovasc Res, January 15, 2008; 77(2): 265 - 273. [Abstract] [Full Text] [PDF]

				S. Sakata, D. Lebeche, N. Sakata, Y. Sakata, E. R. Chemaly, L. F. Liang, Y. Takewa, D. Jeong, W. J. Park, Y. Kawase, et al. Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2356 - H2363. [Abstract] [Full Text] [PDF]

				H. Ly, Y. Kawase, R. Yoneyama, and R. J. Hajjar Gene Therapy in the Treatment of Heart Failure Physiology, April 1, 2007; 22(2): 81 - 96. [Abstract] [Full Text] [PDF]

				K. M. Minhas, R. M. Saraiva, K. H. Schuleri, S. Lehrke, M. Zheng, A. P. Saliaris, C. E. Berry, K. M. Vandegaer, D. Li, and J. M. Hare Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy Circ. Res., February 3, 2006; 98(2): 271 - 279. [Abstract] [Full Text] [PDF]

				L. Lipskaia, F. del Monte, T. Capiod, S. Yacoubi, L. Hadri, M. Hours, R. J. Hajjar, and A.-M. Lompre Sarco/Endoplasmic Reticulum Ca2+-ATPase Gene Transfer Reduces Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Circ. Res., September 2, 2005; 97(5): 488 - 495. [Abstract] [Full Text] [PDF]

				M. Hayase, F. del Monte, Y. Kawase, B. D. MacNeill, J. McGregor, R. Yoneyama, K. Hoshino, T. Tsuji, A. M. De Grand, J. K. Gwathmey, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2995 - H3000. [Abstract] [Full Text] [PDF]

				M. A. F. V. Goncalves, G. P. van Nierop, M. R. Tijssen, P. Lefesvre, S. Knaan-Shanzer, I. van der Velde, D. W. van Bekkum, D. Valerio, and A. A. F. de Vries Transfer of the Full-Length Dystrophin-Coding Sequence into Muscle Cells by a Dual High-Capacity Hybrid Viral Vector with Site-Specific Integration Ability J. Virol., March 1, 2005; 79(5): 3146 - 3162. [Abstract] [Full Text] [PDF]

				Y. Xu, Z. Zhang, V. Timofeyev, D. Sharma, D. Xu, D. Tuteja, P. H. Dong, G. U. Ahmmed, Y. Ji, G. E Shull, et al. The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice J. Physiol., February 1, 2005; 562(3): 745 - 758. [Abstract] [Full Text] [PDF]

				J. C. Hirsch, A. R. Borton, F. P. Albayya, M. W. Russell, R. G. Ohye, and J. M. Metzger Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2314 - H2321. [Abstract] [Full Text] [PDF]

				F. del Monte, D. Lebeche, J. L. Guerrero, T. Tsuji, A. A. Doye, J. K. Gwathmey, and R. J. Hajjar From the Cover: Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling PNAS, April 13, 2004; 101(15): 5622 - 5627. [Abstract] [Full Text] [PDF]

				L. Gepstein, Y. Feld, and L. Yankelson Somatic gene and cell therapy strategies for the treatment of cardiac arrhythmias Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H815 - H822. [Full Text] [PDF]

				H. Post, J. Kajstura, B. Lei, W. C. Sessa, B. Byrne, P. Anversa, T. H. Hintze, and F. A. Recchia Adeno-associated virus mediated gene delivery into coronary microvessels of chronically instrumented dogs J Appl Physiol, October 1, 2003; 95(4): 1688 - 1694. [Abstract] [Full Text] [PDF]

				P. Menasche Skeletal muscle satellite cell transplantation Cardiovasc Res, May 1, 2003; 58(2): 351 - 357. [Abstract] [Full Text] [PDF]

				M. C. LaPointe, X.-P. Yang, O. A. Carretero, and Q. He Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1439 - H1445. [Abstract] [Full Text] [PDF]

				J. C. Wu, M. Inubushi, G. Sundaresan, H. R. Schelbert, and S. S. Gambhir Positron Emission Tomography Imaging of Cardiac Reporter Gene Expression in Living Rats Circulation, July 9, 2002; 106(2): 180 - 183. [Abstract] [Full Text] [PDF]

				J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part II Circulation, May 7, 2002; 105(18): 2223 - 2228. [Full Text] [PDF]